Switching from injectable GLP-1 receptor agonists to oral semaglutide (7 mg daily) dramatically slowed kidney function decline in 36 Japanese patients with type 2 diabetes. Over three years, the annual kidney filtration rate (eGFR) decline improved from -1.92 to -0.26 mL/min/1.73m²/year—an 87% reduction in deterioration rate. Protein spillage in urine (UACR) dropped significantly from 54.3 to 35.8 mg/g, indicating reduced kidney damage. This represents a substantial advance in diabetes care, as kidney disease affects roughly 40% of diabetic patients and remains a leading cause of dialysis worldwide. The oral formulation's superior kidney protection compared to established injectable versions suggests distinct pharmacokinetic advantages, possibly through improved medication adherence or different tissue distribution patterns. The correlation between weight loss magnitude and kidney improvement reinforces the multi-organ benefits of GLP-1 therapy. However, this small retrospective study from a single center requires validation in larger, diverse populations. The finding challenges assumptions about therapeutic equivalence between drug delivery methods and positions oral semaglutide as potentially superior for kidney preservation—a paradigm-shifting consideration for the millions managing diabetes globally.